EP3049080A1 - Substance pour inhiber la calcification tissulaire, la fibrose tissulaire et des maladies liées au vieillissement - Google Patents
Substance pour inhiber la calcification tissulaire, la fibrose tissulaire et des maladies liées au vieillissementInfo
- Publication number
- EP3049080A1 EP3049080A1 EP14777548.0A EP14777548A EP3049080A1 EP 3049080 A1 EP3049080 A1 EP 3049080A1 EP 14777548 A EP14777548 A EP 14777548A EP 3049080 A1 EP3049080 A1 EP 3049080A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- ammonium
- mice
- tissue
- age
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000002308 calcification Effects 0.000 title claims abstract description 33
- 201000010099 disease Diseases 0.000 title claims abstract description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 28
- 239000000126 substance Substances 0.000 title claims abstract description 20
- 230000002401 inhibitory effect Effects 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 14
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 76
- 210000001519 tissue Anatomy 0.000 claims description 46
- 235000019270 ammonium chloride Nutrition 0.000 claims description 38
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 claims description 34
- 229960000571 acetazolamide Drugs 0.000 claims description 31
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 30
- 229960003677 chloroquine Drugs 0.000 claims description 30
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 26
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 25
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 25
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 25
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 claims description 23
- 239000001166 ammonium sulphate Substances 0.000 claims description 23
- 239000004251 Ammonium lactate Substances 0.000 claims description 20
- 206010016654 Fibrosis Diseases 0.000 claims description 20
- 235000019286 ammonium lactate Nutrition 0.000 claims description 20
- 229940059265 ammonium lactate Drugs 0.000 claims description 19
- RZOBLYBZQXQGFY-HSHFZTNMSA-N azanium;(2r)-2-hydroxypropanoate Chemical compound [NH4+].C[C@@H](O)C([O-])=O RZOBLYBZQXQGFY-HSHFZTNMSA-N 0.000 claims description 19
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 claims description 19
- 230000004761 fibrosis Effects 0.000 claims description 18
- 239000000654 additive Substances 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 11
- 230000000996 additive effect Effects 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 6
- 230000007812 deficiency Effects 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 206010040799 Skin atrophy Diseases 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 206010023509 Kyphosis Diseases 0.000 claims description 3
- 208000010428 Muscle Weakness Diseases 0.000 claims description 3
- 206010028372 Muscular weakness Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 208000000509 infertility Diseases 0.000 claims description 3
- 230000036512 infertility Effects 0.000 claims description 3
- 231100000535 infertility Toxicity 0.000 claims description 3
- 201000006370 kidney failure Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
- 230000037390 scarring Effects 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000385 dialysis solution Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 210000001541 thymus gland Anatomy 0.000 claims description 2
- 229960001040 ammonium chloride Drugs 0.000 claims 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 91
- 238000011282 treatment Methods 0.000 description 53
- 229910019142 PO4 Inorganic materials 0.000 description 38
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 38
- 239000010452 phosphate Substances 0.000 description 38
- 108050004036 Klotho Proteins 0.000 description 32
- 102000015834 Klotho Human genes 0.000 description 31
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 28
- 208000004434 Calcinosis Diseases 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 22
- 108010018525 NFATC Transcription Factors Proteins 0.000 description 18
- 102000019276 Nuclear factor of activated T-cells 5 Human genes 0.000 description 16
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 13
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 13
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 13
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 12
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 12
- 238000000540 analysis of variance Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000019491 signal transduction Effects 0.000 description 10
- 101000711846 Homo sapiens Transcription factor SOX-9 Proteins 0.000 description 9
- 102100034204 Transcription factor SOX-9 Human genes 0.000 description 9
- 150000003863 ammonium salts Chemical class 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 8
- 102000043253 matrix Gla protein Human genes 0.000 description 8
- 108010057546 matrix Gla protein Proteins 0.000 description 8
- 230000002188 osteogenic effect Effects 0.000 description 8
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 7
- 230000032683 aging Effects 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 210000003437 trachea Anatomy 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 description 6
- 101001051973 Homo sapiens Fibroblast growth factor 23 Proteins 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 108090000445 Parathyroid hormone Proteins 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 208000010444 Acidosis Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000003982 Parathyroid hormone Human genes 0.000 description 3
- 230000007950 acidosis Effects 0.000 description 3
- 208000026545 acidosis disease Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 210000005119 human aortic smooth muscle cell Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000199 parathyroid hormone Substances 0.000 description 3
- 229960001319 parathyroid hormone Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102100036893 Parathyroid hormone Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GEDVVYWLPUPJJZ-UHFFFAOYSA-N (7-amino-8-methylphenothiazin-3-ylidene)-dimethylazanium;chloride Chemical compound [Cl-].N1=C2C=CC(=[N+](C)C)C=C2SC2=C1C=C(C)C(N)=C2 GEDVVYWLPUPJJZ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100025683 Alkaline phosphatase, tissue-nonspecific isozyme Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 1
- 239000007756 Ham's F12 Nutrient Mixture Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000574445 Homo sapiens Alkaline phosphatase, tissue-nonspecific isozyme Proteins 0.000 description 1
- 101001096159 Homo sapiens Pituitary-specific positive transcription factor 1 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101150045905 NFAT5 gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100029797 Sodium-dependent phosphate transporter 1 Human genes 0.000 description 1
- 208000005475 Vascular calcification Diseases 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000011880 melting curve analysis Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- RIGXBXPAOGDDIG-UHFFFAOYSA-N n-[(3-chloro-2-hydroxy-5-nitrophenyl)carbamothioyl]benzamide Chemical compound OC1=C(Cl)C=C([N+]([O-])=O)C=C1NC(=S)NC(=O)C1=CC=CC=C1 RIGXBXPAOGDDIG-UHFFFAOYSA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000004819 osteoinduction Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/02—Ammonia; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to the use of a substance for reducing tissue calcification and tissue fibrosis and delaying the onset of age-associated diseases and related methods.
- the aging process of a living being is typically characterized by the increased occurrence of diseases and organic dysfunctions. Such so-called age-associated diseases or age syndromes eventually lead to the death of the living being.
- tissue calcification and tissue fibrosis play a crucial role.
- Tissue calcification plays a crucial role, especially in the accelerated aging of patients with renal insufficiency.
- the demise of functioning organ tissue when replaced by connective tissue (fibrosis) plays a central role in renal insufficiency, cirrhosis, Crohn's disease, fibrosing pancreatitis, pulmonary fibrosis, heart failure and scarring.
- tissue fibrosis leads to impairment of the efficacy of peritoneal dialysis.
- Tissue calcification and fibrosis are both stimulated by the transforming growth factor TGF ⁇ 1, which also contributes to the development of Alzheimer 's disease, and signal transduction by tissue calcification also involves activation of alkaline phosphatase and increased expression of the transcription factor Runx2 involved.
- the invention has for its object to find a substance for the reduction of tissue calcification and Organfibrostechnik and age-associated diseases in a living being.
- ammonium sulphate ammonium chloride (NH 4 Cl)
- ammonium chloride NH 4 Cl
- the carbonic anhydrase inhibitor acetazolamide chloroquine
- ammonium nitrate ammonium citrate or ammonium lactate.
- Ammonium sulphate is the salt of ammonia and sulfuric acid. In food technology, ammonium sulphate is used as an additive to regulate acidity and applies to U.S. Pat. Food and Drug Administration generally considered safe (generally recognized as safe [GRAS]). In the European Union it bears the number E517.
- Ammonium citrate is the salt of ammonia and citric acid and is approved in the European Union under number E380.
- Ammonium lactate is the salt of ammonia and lactic acid and is listed in the European Union under number E328 as an acidity regulator.
- Ammonium nitrate is used as fertilizer and in explosives.
- Ammonium chloride with the empirical formula NH 4 Cl which is also referred to as ammonium ummuriate, ammonia salt or sal ammonia, and the CAS no. 12125/02/9, the ammonium salt is hydrochloric acid. It is a colorless, crystalline solid.
- Ammonium chloride is used as an additive in food technology where it bears the number E 510. In medicine, ammonium chloride is used as an expectorant, ie as a cough remover.
- Chloroquine [(RS) -N '- (7-chloroquinolin-4-yl) -N, N-diethyl-pentane-1, 4-diamine] alkalinizes lysosomes and is used against malaria, for immunosuppression, for the treatment of viral diseases and used against tumors.
- the Karboanhydrasehemmer acetazolamide inhibits the enzymatic conversion of bicarbonate to carbon dioxide and therefore can affect the local pH. He is used as a diuretic.
- ammonium sulphate ammonium citrate, ammonium lactate, ammonium nitrate, ammonium chloride (NH 4 Cl), chloroquine or acetazolamide to inhibit signal transduction leading to tissue calcification and tissue fibrosis delaying the onset of age-associated diseases is well known in the art not described.
- the inventors were able to prove on an established cell model that ammonium sulphate, ammonium citrate, ammonium lactate, ammonium nitrate and ammonium chloride (NH 4 Cl) promote the formation of TGF ⁇ 1, a key molecule in the regulation of Tissue calcification and tissue fibrosis inhibiting ( Figure 1). Further, the inventors were able to demonstrate that ammonium sulphate, ammonium nitrate and ammonium chloride inhibit expression of the transcription factor Runx2 ( Figure 2) and that ammonium sulphate, ammonium nitrate, ammonium chloride and chloroquine reduce expression of alkaline phosphatase (Figure 3), both known stimulants of tissue calcification are. Finally, in an established animal model, the inventors were able to demonstrate that the administration of ammonium chloride and acetazolamide resulted in a marked prolongation of life ( Figure 19) and decreased or prevented tissue and vessel calcification ( Figures 12-18).
- use is understood to mean that at least one of the substances mentioned induces the claimed action.
- use of said substances in the context of monotherapies can be carried out using ammonium sulphate, ammonium citrate, ammonium lactate, ammonium nitrate, ammonium chloride (NH 4 Cl), chloroquine and acetazolamide as active ingredient or sole active ingredient.
- combination therapies are also possible in which two or more of these agents are used simultaneously.
- age-associated diseases are selected from the group consisting of atherosclerosis, pulmonary emphysema, skin atrophy, muscle weakness, immune deficiency weakness, infertility, kyphosis, disturbed CaP0 4 metabolism, osteoporosis, immunodeficiency (thymus regeneration), and neurodegeneration ,
- tissue fibrosis is based on a disease selected from the group consisting of cirrhosis of the liver, Crohn's disease, fibrosing pancreatitis, pulmonary fibrosis, cardiac insufficiency, scarring, fibrosis in peridone dialysis, Alzheimer 's disease.
- the measure has the advantage that substances are provided with which important fibrosing diseases can be treated prophylactically and therapeutically.
- Ammonium sulphate, ammonium citrate, ammonium lactate, ammonium nitrate, ammonium chloride (NH 4 Cl), chloroquine and acetazolamide can be active substances in a pharmaceutical composition, which are preferably designed for oral, rectal, parenteral, intraperitoneal, local or transdermal administration is.
- the pharmaceutical composition may preferably be in the form of a powder, tablet, juice, drops, dialysis fluid, capsule, suppository, solution, injection solution, aerosol, ointment, rinse, patch, pellet, dragee or modified release dosage form.
- compositions for adult human administration may provide daily units of about 25 g ammonium sulphate, 25 g ammonium citrate, 35 g ammonium lactate, 25 g ammonium nitrate, 20 g ammonium chloride (NH 4 Cl), 900 mg chloroquine and 800 mg acetazolamide.
- the person skilled in the art can also provide deviating other absolute amounts. This measure has the advantage that the active ingredient is provided in an absolute amount that achieves the desired effects.
- the pharmaceutical composition may contain a pharmaceutically acceptable carrier and optionally other additives well known in the art. They are described, for example, in the paper by Kibbe A., Handbook of Pharmaceutical Excipients, Third Edition, American Pharmaceutical Association and Pharmaceutical Press 2000. Additives include any compound or composition which is advantageous for the inventive use of the composition, including salts, binders, solvents, dispersants, and other substances commonly used in the formulation of medicaments.
- ammonium sulphate, ammonium citrate, ammonium lactate, ammonium nitrate, ammonium chloride (NH 4 Cl), chloroquine and acetoazamide can be used as additive (e) in a food product.
- the preferred concentration of the active ingredient can be readily determined by methods known to those skilled in the art, for example by titration experiments in which various concentrations are used.
- the effective amount can be determined individually.
- the concentration depends on the specific age-associated disease to be treated, the course, the severity, the patient to be treated, in particular on its immunological condition, gender, age, pre-existing conditions, etc.
- concentration When used in drinks the concentration of about 25 g of ammonium sulphate, 25 g of ammonium citrate, 35 g of ammonium lactate, 25 g of ammonium nitrate, 20 g of ammonium sulphate, chloride (NH 4 Cl), chloroquine 800 mg or acetazolamide 800 mg.
- NH 4 Cl ammonium sulphate
- This measure has the advantage that the active ingredient or the additive is already provided in a concentration which ensures the desired effects.
- Another object of the invention relates to a process for the preparation of a pharmaceutical composition for reducing tissue calcification and Gewebsfibrostechnik and for delaying the onset of age-associated diseases, comprising the following steps:
- the active ingredient is selected from the group consisting of: ammonium sulphate, ammonium chloride (NH 4 Cl), acetazolamide, chloroquine, ammonium nitrate, ammonium citrate and ammonium lactate.
- Another object of the present invention relates to a method for producing a food product for reducing tissue calcification and Gewebsfibrostechnik and for delaying the onset of age-associated diseases, comprising the following steps:
- the additive is selected from the group consisting of: ammonium sulphate, ammonium chloride (NH 4 Cl), acetazolamide, chloroquine, ammonium nitrate, ammonium citrate and ammonium lactate.
- Another object of the present invention relates to a method for reducing tissue calcification and Gewebsfibrostechnik and for delaying the onset of age-associated diseases, which comprises the administration of a substance to the subject, wherein the substance is selected from the group consisting of: ammonium sulphate , Ammonium chloride (NH 4 Cl), acetazolamide, chloroquine, ammonium nitrate, ammonium citrate and ammonium lactate.
- a substance selected from the group consisting of: ammonium sulphate , Ammonium chloride (NH 4 Cl), acetazolamide, chloroquine, ammonium nitrate, ammonium citrate and ammonium lactate.
- the substances can be used individually as sole active ingredients or additives or in combination.
- TGF ⁇ 1 mRNA shows the expression of TGF ⁇ 1 mRNA in human smooth aortic smooth muscle cells (HAoSMCs) at normal phosphate concentration (white column) and after increasing the phosphate concentration by addition of 2 mM ⁇ -glycerophosphate to the stimulus mulation of osteogenic signal transduction in the absence (gray column) and presence (black columns) of different ammonium salts (0.5 mM each).
- *** (p ⁇ 0.001) shows statistically significant difference to normal phosphate concentration; # (p ⁇ 0.05), ##
- Fig. 3 shows the expression of alkaline phosphatase mRNA in human smooth aortic smooth muscle cells (HAoSMCs) at normal phosphate concentration (white column) and after increasing the phosphate concentration by adding 2 mM ⁇ -glycerophosphate to stimulate osteogenic signal transduction in the absence (gray column) and presence (black columns) of various ammonium salts (Figure 3A) (0.5 mM each) and chloroquine (100 ⁇ ) ( Figure 3B).
- Fig. 4 shows the expression of NFAT5 (Nuclear factor of activated T-cells 5) in aortas of klot o + l + - (light bars) and / / oi / o hm mice (dark bars), either without (control)? and with NH 4 Cl treatment.
- NFAT5 Nuclear factor of activated T-cells 5
- Fig. 5 shows the expression of NFAT5 (A) and SOX9 (B) in human smooth
- Aortic smooth muscle cells at normal phosphate concentration (white columns) and after increasing the phosphate concentration by adding 2mM ⁇ -glycerophosphate to stimulate osteogenic signal transduction in the absence (black columns) and presence (gray columns) of ammonium chloride ( 500 ⁇ ).
- (n 6-8) ** (p ⁇ 0.01) shows statistically significant difference to normal phosphate concentration; # (p ⁇ 0.05), shows statistically significant difference to increased phosphate concentration in the absence of ammonium chloride (ANOVA).
- Fig. 6 shows the expression of NFAT5 (A), SOX9 (B), CBFA1 / RUNX2 (C) and
- HASMCs human smooth aortic smooth muscle cells
- TGF-beta 10 ng / ml
- TGFB1 normal phosphate concentration
- Fig. 12 shows the histology of trachea, lung, kidney, stomach and vessels
- mice without (untreated) or with (treated) (NH 4 ) 2 S0 - treatment.
- Fig. 13 shows the histology of vessels from / c / of / 70 hm mice without (untreated) treatment, with (treated) (NH 4 ) 2 S0 4 - or with NH 4 N0 3 treatment.
- Fig. 14 shows the histology of trachea, lung, kidney, stomach and vessels
- mice without (untreated) or with (treated) NH 4 N0 3 - treatment.
- Fig. 15 shows the histology of hearts from / / of / 70 hm mice without (untreated) treatment and with NH N0 3 treatment
- Fig. 16 shows the histology of trachea, lung, kidney, stomach and vessels
- FIG. 17 shows the histology of the trachea, lung, kidney, stomach and blood vessels from / / oi /? O hm mice without (untreated) or with (treated) Aze- tazolamid treatment.
- Fig. 18 shows the histology of trachea, lung, kidney, stomach and vessels
- mice without (untreated) or with (treated) chloroquine diphosphate treatment.
- (p ⁇ 0.05, Wilcoxon, log rank) (p ⁇ 0.05, Wilcoxon, log rank).
- HASMCs human primary smooth muscle cells
- Invitrogen Aortic human primary smooth muscle cells
- Waymouth's MB 752/1 medium and Ham's F-12 nutrient mixture (1: 1, Gibco, Life Technologies) with 10% FBS added (Gibco , Life Technologies) and 100 U / ml penicillin and 100 ⁇ g / ml streptomycin (Gibco, Life Technologies).
- FBS FBS-containing bovine serum
- the cells were treated with 2 mM ⁇ -glycerophosphate (Sigma-Aldrich) for 24 hours with or without the simultaneous addition of 0.5 mM ammonium salts or 100 ⁇ M chloroquine diphosphate (Sigma-Aldrich).
- RT-PCR Quantitative real-time polymerase chain reaction
- RNA samples were used for the reverse transcription of the RNA with oligo (dT) 12- i8 primers (Invitrogen) and SuperScriptIII reverse transcriptase (Invitrogen).
- Quantitative real-time PCR was performed using an iCycler iQ TM Real-Time PCR Detection System (Bio-Rad Laboratories) and iQ TM Sybr Green Supermix (Bio-Rad Laboratories) according to the manufacturer's instructions. The following primers were used (5'-> 3 'orientation):
- TN alkaline phosphatase fw G G GACTG GTACTC AG ACAACG (SEQ ID NO: 1);
- TN alkaline phosphatase rev GTAGGCGATGTCCTTACAGCC (SEQ ID NO: 2);
- RUNX2 fw GGAAGGGCTTGATTGACGTG (SEQ ID NO: 3);
- RUNX2 rev CAGAACCAAACATAGCACTGACT (SEQ ID NO: 4);
- TGFB1 fw CAATTCCTGGCGATACCTCAG (SEQ ID NO: 5);
- TGFB1 rev GCACAACTCCGGTGACATCAA (SEQ ID NO: 6).
- GAPDH fw GAGTCAACGGATTTGGTCGT (SEQ ID NO: 7);
- GAPDH rev GACAAGCTTCCCGTTCTCAG (SEQ ID NO: 8);
- NFAT5 rev GTCCGTGGTAAGCTGAGAAAG (SEQ ID NO: 10);
- SOX9 fw: AGCGAACGCACATCAAGAC (SEQ ID NO: 1 1);
- SOX9 rev CTGTAGGCGATCTGTTGGGG (SEQ ID NO: 12).
- Nfat51w CTGTAGGCGATCTGTTGGGG (SEQ ID NO: 13);
- Nfat5 rev CTG GTG CTCATGTTACTG AAGTT (SEQ ID NO: 14);
- Gapdh lw AGGTCGGTGTGAACGGATTTG (SEQ ID NO: 15);
- Gapdh rev TGTAGACCATGTAGTTGAGGTCA (SEQ ID NO: 16).
- the specificity of the PCR products was checked by melting curve analysis and agarose gel electrophoresis. All PCRs were carried out twice and the multiples of the mRNA quantity were calculated by the 2 _ ⁇ method with GAPDH as internal reference.
- mice Male and female hypomorphic / oi / o mice (klotho m ) were compared with male and female wild type mice (klotho + / + ).
- the origin of the mice, breeding and genotyping are described in the prior art; see. Kuro-o et al. (1997), Mutation of the mouse gene leads to a syndrome reminding aging, Nature 390: 45-51.
- backcrossings > 9 generations
- congenic strains of the / o / o hm mice were prepared and used in this study.
- mice had random access to water or an aqueous solution of (NH 4 ) 2 SO 4 (0.14M), NH 4 Cl (0.28M), NH 4 NO 3 (0.28M), acetazolamide (800 mg / l) and chloroquine diphosphate (0.288 mg / ml) and were fed with control diet (Sniff, Soest, Germany).
- the treatments with NH 4 Cl (0.28 M) or acetazolamide (800 mg / L) began with parental generation and continued throughout pregnancy until the offspring were killed.
- mice were anesthetized with diethyl ether (Roth, Düsseldorf, Germany) and by puncturing the retro-orbital plexus blood samples were taken from 50 to 200 ⁇ in capillaries containing heparin.
- the phosphate and calcium concentrations in the plasma were determined using a photometric method (FUJI FDC 3500i, Sysmex, Nordstedt, Germany).
- Plasma FGF23 and PTH levels were determined using commercial ELISA kits (FGF23: Immunodiagnostics, Boston, USA, PTH: Immunotopics, San Diego, USA, MPG: Cloud-Clone Corporation, Houston, USA).
- the measurement of the concentration of Caicitriol [1, 25 (OH) -Vitamin D 3 ] in the plasma was also under Using a commercial ELISA kit (IDS, Boldon, United Kingdom).
- the ammonia concentration was measured enzymatically using glutamate dehydrogenase with NADPH as cofactor.
- the evaluation was also carried out with a photometric method (ADVIA 1650 analyzer, Siemens, Fernwald, Germany).
- mice were male and / / oi / o + / + mice (aged 8 weeks) were male and / / oi / o hm Mice (age: 8 weeks), with and without treatment of aqueous solutions of (NH 4 ) 2 SO 4 (0.14M), NH 4 Cl (0.28M), NH 4 NO 3 (0.28M) and chloroquine ( 0.288 mg / ml), or embedded in paraffin in female animals without and with acetazeolamide treatment (800 mg / l in drinking water), cut into slices of 2 to 3 ⁇ and stained with H & E and Kossa; see. Mossbrugger et al.
- Klotho is a transmembrane protein related to the ⁇ -glucuronidase. Decreased production of this protein has been observed in patients with chronic renal failure, often associated with degenerative processes such as atherosclerosis, osteoporosis and skin atrophy. Mutations in this protein could be linked to aging processes.
- hypomorphic mice In the investigated mouse model, the / / o /? O expression is massively reduced by a defect in the klotho gene. Affected mice are referred to as hypomorphic mice.
- the lack of klotho leads to a syndrome that resembles human aging. More specifically, in these animals, accelerated appearance of tissue and / or vascular calcification, arteriosclerosis, pulmonary emphysema, skin atrophy, muscle weakness, immune deficiency, infertility, kyphosis, impaired CaP0 4 metabolism, osteoporosis, immune deficiency (thymic regression), hearing loss and neurodegeneration observed.
- the affected animals also have a significantly reduced life expectancy and are infertile.
- FIG. 1 shows the expression of TGF ⁇ 1 mRNA in human smooth aortic muscle cells (HAoSMCs).
- HOSMCs human smooth aortic muscle cells
- the cells were treated with 2 mM ⁇ -glycerophosphate to stimulate osteogenic signal transduction.
- the increased phosphate concentration resulted in a significant increase in TGF ⁇ 1 mRNA expression.
- This increase was mitigated by the addition of various ammonium salts (0.5 mM) (ammonium lactate, ammonium citrate, ammonium sulfate) or even prevented (ammonium chloride, ammonium nitrate).
- FIG. 2 shows the expression of Runx2 mRNA in human smooth aortic smooth muscle cells (HAoSMCs).
- HOSMCs human smooth aortic smooth muscle cells
- ALP alkaline phosphatase
- HOSMCs human aortic smooth muscle cells
- Fig. 3A shows the suppression of the expression increase by Ammonium chloride, ammonium nitrate and ammonium sulfate.
- Fig. 3B shows the suppression of ALP mRNA expression increase by chloroquine (100 ⁇ ).
- FIG. 4 shows that the expression of the transcription factor NFAT5 in aortas of klotho hm mice is markedly increased compared to the klotho + / + mice.
- Treatment with NH 4 Cl (0.28 M) leads to a normalization of transcription levels.
- Fig. 5 shows the transcription levels of NFAT5 and SOX9 in human smooth aortic smooth muscle cells (HAoSMCs). Stimulation with 2 mM ⁇ -glycerophosphate increased transcription levels, while concomitant treatment with NH 4 Cl reduced expression again.
- Fig. 6 shows the transcription levels of NFAT5, SOX9, Runx2 and ALP in human aortic smooth muscle cells after transfection with NFAT5.
- concurrent treatment with NH4CI reduced the expression of the respective genes of the cells transfected with empty vector back to a normal level, the expression in the NFAT5 transfected cells remained high.
- Fig. 7 shows the increase of the transcription level of NFAT5 in human aortic smooth muscle cells under treatment with TGF beta as well as 2mM ⁇ -glycerophosphate. While treatment of the cells with NH 4 Cl could reverse the increase in NFAT5 transcription triggered by the treatment with 2 mM ⁇ -glycerophosphate, the expression was still significantly increased with simultaneous treatment with TGF beta.
- FIG. 8 shows the significant growth deficits of untreated hypomorphic (klotho m ) mice in comparison to their wildtype throwing siblings (klotho + / + ).
- the growth deficit of the / / offrc ⁇ mice could be almost completely abolished by treatment with NH 4 Cl (klotho m NH 4 Cl).
- Wild type mice showed no growth stimulation on treatment with NH 4 Cl (klotho + / + NH 4 Cl).
- the body weight of untreated klotho mice (control) is significantly lower than that of untreated / oi / o + / + mice.
- the portionsdefz was almost completely abolished (B).
- FIG. 10A shows the plasma phosphate levels of the animals, which were significantly higher than / / oi /? O + were with / / oi /? O hm mice + / mice.
- Treatment with NH 4 Cl did not alter the plasma metabolism.
- the plasma concentrations of Ca ++ in untreated / / oi /? O hm mice were significantly higher than in / / oi /? O + / + mice.
- the NH 4 Cl treatment resulted tend to a decrease in Ca ++ concentrations in the plasma of / / oi /? O hm mice, but did not reach statistical significance.
- Also shown in Fig. 10 are the plasma concentrations of 1, 25 (OH) 2 D 3 (Caicitriol), FGF23 and parathyroid hormone.
- the levels of 1, 25 (OH) 2 D 3 and FGF23 were significantly higher, those of parathyroid hormone were significantly lower in / / of / 70 hm mice than in / / oi /?
- Fig. 1 the plasma concentrations of Ca ++ , phosphate and 1, 25 (OH) 2 D 3 of / oi / o + / + mice and / oi / o hm mice are respectively presented with and without treatment with acetazolamide. Neither the concentration of 1, 25 (OH) 2 D 3 nor that of phosphate was affected by the treatment. Also, the calcium levels of the treated / / oi /? O hm mice was slightly increased as before, but showed neither the untreated / / oi /? O hm mice nor to the / / oi /? O + / + mice a significant difference. The levels of matrix Gla protein (MGP) in the animals' plasma could also be completely normalized by treatment with acetazolamide.
- MGP matrix Gla protein
- mice observed in / / oi / with an age of 8 weeks strong calcifications in all tissues analyzed, such as. In the trachea, lung, kidney, Stomach and the vascular tissues.
- the calcification in / m o / hm mice could be achieved by treatment with (NH 4 ) 2 S0 4 (FIGS. 12, 13), NH 4 N0 3 (FIGS. 13, 14, 15) and NH 4 Cl (FIG. Fig. 16) are greatly reduced.
- FIG. 17 also shows histological sections of selected organs / / oi /? O hm mice.
- the treatment of the animals with acetazolamide also led to a significant reduction of calcifications in the analyzed tissues.
- Fig. 18 shows histological sections of selected organs of / / / o hm mice and / or? O hm mice under treatment with chloroquine diphosphate.
- the treatment of the animals with the chloroquine salt also led to a significant reduction of calcifications in the analyzed tissues.
- the inventors provide with ammonium sulphate, ammonium chloride (NH 4 Cl), acetazolamide, chloroquine, ammonium nitrate, ammonium citrate and ammonium lactate, substances which are suitable for preventing tissue calcification and tissue fibrosis and delaying the onset of age-associated diseases and thus the Extend the life of a living being. This is partly due to the Influence on the expression of calcification and fibrosis markers in cell culture and the impressive effects of ammonium chloride and acetazolamide on an established animal model. The correspondingly treated animals show markedly reduced age syndromes, impressively illustrated by tissue and vessel calcification, and live significantly longer than untreated animals.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne une substance servant à réduire les processus de calcification tissulaire et de fibrose tissulaire, et à retarder l'apparition de maladies liées au vieillissement d'un être vivant, ainsi que des procédés associés.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102013110608.0A DE102013110608A1 (de) | 2013-09-26 | 2013-09-26 | Substanz zur Hemmung von Gewebskalzifizierung, Gewebsfibrosierung und altersassoziierten Erkrankungen |
PCT/EP2014/070333 WO2015044180A1 (fr) | 2013-09-26 | 2014-09-24 | Substance pour inhiber la calcification tissulaire, la fibrose tissulaire et des maladies liées au vieillissement |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3049080A1 true EP3049080A1 (fr) | 2016-08-03 |
Family
ID=51655703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14777548.0A Withdrawn EP3049080A1 (fr) | 2013-09-26 | 2014-09-24 | Substance pour inhiber la calcification tissulaire, la fibrose tissulaire et des maladies liées au vieillissement |
Country Status (5)
Country | Link |
---|---|
US (1) | US20160346320A1 (fr) |
EP (1) | EP3049080A1 (fr) |
CN (1) | CN105939711A (fr) |
DE (1) | DE102013110608A1 (fr) |
WO (1) | WO2015044180A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109568315B (zh) * | 2018-11-15 | 2022-04-01 | 常晓天 | 碳酸酐酶抑制剂在制备抗动脉粥样硬化药物中的应用 |
EP4247351A1 (fr) * | 2020-11-20 | 2023-09-27 | Tsirikos-Karapanos, Nikolaos | Formulation de chlorure d'ammonium d'aide à la défense naturelle humaine contre des virus |
CN113855674A (zh) * | 2021-11-05 | 2021-12-31 | 中国科学院动物研究所 | 氯喹的应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3671633A (en) * | 1971-05-10 | 1972-06-20 | American Cyanamid Co | Process for tabletting acetazolamide |
US4466960A (en) * | 1983-10-18 | 1984-08-21 | Thompson Medical Co., Inc. | Analgesic-diuretic compositions |
NL8401782A (nl) * | 1984-06-04 | 1986-01-02 | Jan Willem Bins | Therapeutisch preparaat met ammoniumnitraat als werkzame stof. |
US5389677B1 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Method of treating wrinkles using glycalic acid |
US5082487A (en) * | 1988-04-11 | 1992-01-21 | Allied-Signal Inc. | Solutions of ammonium sulfate, ammonium nitrate and urea, with high nitrogen and sulfur content, having low salt-out temperatures |
DE19649732A1 (de) * | 1996-11-30 | 1998-06-04 | Andreas Schulz | Alkoholisches Mixgetränk |
US6391899B1 (en) * | 1998-07-17 | 2002-05-21 | North Shore—Long Island Jewish Research Institute | Compounds and compositions for treating tissue ischemia |
CN1120002C (zh) * | 1999-10-09 | 2003-09-03 | 兰州凯瑞中药科技开发有限公司 | 硝酸铵在制药、食品和保健品中的应用 |
US7977385B2 (en) * | 2000-03-02 | 2011-07-12 | Numoda Biotechnologies, Inc. | Agents for corneal or intrastromal administration to treat or prevent disorders of the eye |
MXPA04008776A (es) * | 2002-03-14 | 2005-04-19 | Vitreo Retinal Technologies In | Agentes para administracion cornea o intraestromal, para tratar o evitar desordenes del ojo. |
GR20020100405A (el) * | 2002-09-12 | 2004-05-24 | Διαμαντης Ιωαννου Κιασσος | Νεα χρηση του nh4 cl για την θεραπεια της ηπατικης ινωσεως νεκρωσεως και εγκεφαλοπαθιας οξειας και χρονιας ηπατικης ανεπαρκειας. νεα χρηση του nh4 cl για την θεραπεια της υπερχολερυθριναιμιας, υπερτρασανεμιας προκιρρωτικων και κιρρωτικων καταστασεων του ηπατος, ως επισης για την προληψη της μετατροπης των ως ανω νοσηματων εις νεοπλασματα του ηπατος. |
US20050036953A1 (en) * | 2003-08-13 | 2005-02-17 | Moshe Arkin | Topical compositions of ammonium lactate |
WO2005016329A1 (fr) * | 2003-08-13 | 2005-02-24 | Agis Industries (1983) Ltd. | Compositions topiques a base d'uree et de lactate d'ammonium |
US20050191365A1 (en) * | 2004-02-26 | 2005-09-01 | Creasey David H. | Antimicrobial food additive and treatment for cooked food, water and wastewater |
CA2616537A1 (fr) * | 2005-07-27 | 2007-02-01 | University Of Florida Research Foundation, Inc. | Petits composes corrigeant un mauvais repliement des proteines et utilisations de ceux-ci |
US20070110707A1 (en) * | 2005-11-04 | 2007-05-17 | Washington University | Method of treating diseases involving non-enzymatic glycation |
WO2008064296A1 (fr) * | 2006-11-22 | 2008-05-29 | Envivo Pharmaceuticals, Inc. | Procédé de traitement de troubles neurologiques avec des inhibiteurs d'anhydrase carbonique |
US8614236B2 (en) * | 2006-12-12 | 2013-12-24 | University Of Washington | Methods of treating pulmonary disease using acetazolamide and structurally related derivatives |
JP2013529660A (ja) * | 2010-06-29 | 2013-07-22 | バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー | 環状カルボニルアミジン類を含む改善された殺虫剤組成物 |
EP2616082A2 (fr) * | 2010-09-17 | 2013-07-24 | Mount Sinai School Of Medicine | Méthodes et compositions utilisées pour inhiber l'autophagie dans le traitement de la fibrose |
-
2013
- 2013-09-26 DE DE102013110608.0A patent/DE102013110608A1/de not_active Ceased
-
2014
- 2014-09-24 EP EP14777548.0A patent/EP3049080A1/fr not_active Withdrawn
- 2014-09-24 CN CN201480064440.1A patent/CN105939711A/zh active Pending
- 2014-09-24 WO PCT/EP2014/070333 patent/WO2015044180A1/fr active Application Filing
- 2014-09-24 US US15/025,383 patent/US20160346320A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE102013110608A1 (de) | 2015-03-26 |
CN105939711A (zh) | 2016-09-14 |
WO2015044180A1 (fr) | 2015-04-02 |
US20160346320A1 (en) | 2016-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69836321T2 (de) | Pflanzenextrakte mit appetitzügelnder Aktivität | |
DE69731386T2 (de) | Verfahren zur behandlung von asthma mit o-desulfatisiertem heparin | |
DE2036114B2 (de) | Wäßriges Tetramisolpräparat | |
WO2015044180A1 (fr) | Substance pour inhiber la calcification tissulaire, la fibrose tissulaire et des maladies liées au vieillissement | |
DE69922409T2 (de) | Verwendung von natürlichen antisekretorischen Proteinen | |
DE10035227A1 (de) | Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind | |
DE2329158A1 (de) | Heilmittel zur behandlung der ketonaemie und der osteomalazie bei vieh, insbesondere hornvieh | |
DE60216292T2 (de) | Calciumtrifluoracetat mit zytotoxischer wirkung | |
EP0065246A2 (fr) | Procédé de production de substances actives anaboliques favorisant la respiration et de faible poids moléculaire pour des fins prophylactiques, thérapeutiques et pour des techniques de culture de cellules et de tissus | |
WO2001054676A2 (fr) | Formulations destinees a des etats de deshydratation | |
EP3352763A1 (fr) | Substance pour la prophylaxie et le traitement d'infections provoquées par des virus influenza | |
DE10326821A1 (de) | Pharmazeutische Kombinationspräparate zur Krebstherapie | |
DE2348805A1 (de) | Nahrungsmittel-komposition und verfahren zur herstellung derselben | |
DE1900124A1 (de) | Neue pharmazeutische Zusammensetzungen auf der Basis von Polystyrolpolymeren | |
WO2012123561A2 (fr) | Agent pour la prophylaxie et le traitement de maladies et troubles séniles et l'allongement de la durée de vie | |
DE60206545T2 (de) | Zusammensetzung zum Trinken/Essen enthaltend AGARICUS BLAZEI MURRILL | |
WO2014056779A1 (fr) | Médicament destiné à la prévention et au traitement d'une maladie neurodégénérative | |
EP1667673B1 (fr) | Huiles vegetales contenant de l'acide alpha-linolénique contre le diabète | |
DE4319554A1 (de) | Verwendung von etherischen Ölen zur Suppression der Freisetzung von Arachidonsäure | |
DE60020888T2 (de) | Zusatz aus kräutern zur behandlung von kognitiven störungen aufgrund von östrogenverlust | |
EP1033131B1 (fr) | Composition pour boisson ayant un effet d'aversion pour l'alcool | |
DE102004008375B4 (de) | Verwendung von physiologisch verträglichen Ascorbatverbindungen in Kombination mit einem Sympathomimetikum als lokales Therapeutikum für Schleimhäute der Atemwege | |
DE102005031363A1 (de) | Mittel mit Anti-Aging-Effekt | |
DE102012103096A1 (de) | Prophylaxe und Behandlung einer Gefäßkalzifizierung | |
DE3303398C2 (fr) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20160318 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20180404 |